阿司匹林与患有心房的重症患者的死亡率之间的关联:基于模拟-IV数据库的回顾性队列研究
Meijuan Zhang1, Yadong Zuo1, Zhanquan Jiao1
1Department of Cardiology, Tianjin Haihe Hospital, Tianjin, China.
Frontiers in cardiovascular medicine
|June 3, 2024
概括
阿司匹林的使用可能会降低心房动 (AF) 严重病患者的死亡率. 需要进一步的随机试验来证实这种关联及其在AF患者护理中的好处.
科学领域:
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心房动 (AF) 在重症患者中很常见,有效的治疗选择有限.
- 在重症监护机构管理AF面临重大挑战.
研究的目的:
- 调查阿司匹林使用与AF诊断的危急病患者的死亡率之间的关联.
- 在这个患者群体中,比较阿司匹林和非阿司匹林使用者之间的死亡结果.
主要方法:
- 一项使用密集护理医疗信息中心 (MIMIC) 数据库的队列研究.
- 包括13,330名患有AF的重症患者,比较阿司匹林 (4,421) 和非阿司匹林 (8,909) 用户.
- 使用Kaplan-Meier和Cox比例危险回归模型对28天,90天和1年的死亡率进行分析.
主要成果:
- 阿司匹林使用与明显较低的28天,90天和1年死亡率有关 (HRs从0.64到0.67).
- 服用阿司匹林降低的死亡风险在65岁以下没有心力衰竭或心肌梗塞史的患者中更为明显.
- 总的死亡率为17.5% (28天),23.9% (90天) 和32.9% (1年).
结论:
- 阿司匹林的使用可能与严重病情的AF患者全因死亡率的降低有关.
- 进一步的随机对照试验对于验证这些发现和确认阿司匹林的作用至关重要.
- 研究阿司匹林在特定亚组中的益处需要进一步关注.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421


